Clinical Trial Update: Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ranolazine to reduce ischemia in non-ST-elevation acute coronary syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Ischemia
• Non-st-elevation Acute Coronary Syndrome

Drugs mentioned

• Ranexa (ranolazine)

Snippet

Sponsor: Gilead Sciences | Conditions: Myocardial Ischemia | Phase 3 | Status: COMPLETED